Twitxy Saved

IMCrit

Verified account This account is verified. Learn more

@IM_Crit_

Intensivist | Internal Medicine
Thinking out loud about the ICU
ICU Stories • Snapshots • Pearls • Visuals • Evidence • News • occasional hot takes
☕🍩🥐🍫
Joined April 2020
765 Following 59K Followers 15K Posts

Latest posts 5

Pinned post

IMCrit Verified account @IM_Crit_
#Thiamine in the ICU: 10 high-yield pearls

1. Unexplained lactate? Think thiamine.

Thiamine is required for pyruvate dehydrogenase. Deficiency blocks conversion of pyruvate to acetyl-CoA, shunting pyruvate toward lactate and impairing mitochondrial aerobic metabolism. Thus, thiamine deficiency belongs in the differential diagnosis for otherwise unexplained lactic acidosis.

2. Thiamine deficiency in the ICU is not rare.

~30-70% of critically ill patients are thiamine-deficient. Many arrive deficient; others develop deficiency during critical illness because of increased metabolic demand, inadequate intake, or losses.

3. The bedside phenotype is more important than waiting for a thiamine level.

High-risk situations include malnutrition, alcohol-related liver disease, bariatric surgery, renal replacement therapy, polyuria/DKA, chronic diuretic therapy, unexplained encephalopathy, unexplained lactate elevation, and sepsis.

4. Starting nutrition can unmask the deficiency.

Glucose administration increases carbohydrate metabolism and thiamine utilization. A malnourished patient may therefore develop rising lactate after initiation of enteral/parenteral nutrition. Refeeding syndrome is not simply a phosphorus/potassium problem; thiamine deficiency can be central to its pathophysiology.

5. Dialysis and polyuria are major clues.

Thiamine can be lost during continuous RRT, hemodialysis, and peritoneal dialysis. Renal losses also rise with polyuria, including the diuretic phase of AKI, post-transplant polyuria, DKA, and chronic diuretic therapy in heart failure.

6. Do not wait for the classic Wernicke's triad.

Altered mental status, ocular abnormalities, and gait ataxia are rarely all present together. I think I have seen it only a few times. In an at-risk ICU patient with otherwise unexplained encephalopathy, absence of the complete triad should not reassure you.

7. A plasma thiamine concentration is not a great “rule-out” test.

Testing is often unavailable and expensive, and blood concentration does not necessarily reflect tissue thiamine status. I don't even remember when I last ordered the test (if ever...). Erythrocyte transketolase activity is physiologically more informative, but its cutoffs are poorly defined. Just recognize the risk population and consider a therapeutic trial rather than wait for laboratory confirmation.

8. The sepsis data are more nuanced than “thiamine works” or “thiamine doesn't work.”

Thiamine is not expected to improve hard outcomes in the overall septic-shock population. Some subgroup analyses and meta-analyses suggest signals for improved lactate clearance and organ function, particularly renal outcomes. I don't consider it a magic drug...

9. Thiamine alone ≠ HAT (hydrocortisone + ascorbic acid +thiamine) therapy.

Do not interpret negative trials of HAT as proof that correcting thiamine deficiency is useless. Large HAT RCTs failed to demonstrate the dramatic clinical benefit initially claimed, and a VICTAS secondary analysis raised concerns about longer-term outcomes. That is a different question from replacing thiamine in a patient likely to be deficient.

10. The kidney may be an important target organ.

Renal tubular cells are highly energy dependent. Across secondary analyses, observational data, and meta-analytic evidence, thiamine supplementation -particularly in deficient patients- shows a signal toward less AKI progression, better renal recovery, and less need for RRT, although individual RCTs have not consistently demonstrated significant benefit in unselected populations.

Rule of thumb:
“⬆️ lactate + risk factor + no good explanation" → think B1 deficiency”

Especially think about it when you see malnutrition/refeeding, alcoholism/cirrhosis, dialysis, polyuria/DKA, chronic diuretics, unexplained encephalopathy, sepsis, or otherwise unexplained persistent hyperlactatemia.

I usually include it in the admission orders for most of my ICU patients along with DVT and GI prophylaxis...!

Thiamine deficiency behaves less like an obscure vitamin deficiency and more like a potentially reversible form of mitochondrial energy failure. Or that's how I like to think about it.

#foamed #foamcc #meded
14 replies 159 reposts 651 likes 79K views View on X
IMCrit Verified account @IM_Crit_
#ICU Evidence #008: 2026 SCAI SHOCK Classification Update: Summary and Comments

@SCAI just updated its cardiogenic shock classification (Baran and Naidu, co-chairs), endorsed by ACC, EACTS, ISHLT, SCCM, STS and others. It’s still “article in press” in JSCAI. The method is a narrative literature review plus consensus voting (75% agreement). The pyramid stays A to E. The definitions and guidance around them have changed.

Summary:

Philosophy: stage comes from the exam, labs and hemodynamics, not simply from what we did. Pressors, inotropes, MCS and ECLS don’t define the stage by themselves, and the stage should be reassessed serially.

What changed:

A (at risk) is better defined. It now focuses on meaningful risk from the combination of baseline vulnerability and an acute stressor, disease or procedure: large ACS, high-risk PCI, VT ablation, structural interventions, advanced HF.

B vs C depends on HYPOPERFUSION, not hypotension. Low BP with good perfusion is B. Hypoperfusion with a normal BP is C.

D means the initial strategy is failing: worsening or non-improving hypoperfusion or lactate despite treatment. They propose reassessing at 2–3 hours for clear worsening and up to 4–6 hours to judge failure to respond, and admit the best interval is uncertain.

E is actual or impending collapse: features include lactate ≥8, pH ≤7.2, bolus pressors or profound hypotension despite maximal support.

Recovery: a patient who normalizes perfusion on ECMO or MCS can be restaged as C while still on support.

“Arrest” modifier: reserved for cardiac arrest when neurologic recovery remains uncertain. Cardiac arrest itself does not determine the SCAI stage.

Phenotypes: AMI, HF, RV-predominant, mixed (about 20% of CICU shock), postcardiotomy and pediatric shock each get specific discussion. In HF, preserved BP and even a normal lactate do not necessarily mean adequate perfusion.

Implementation: staging across EMS, ED, cath lab and ICU, serial nursing assessment, point-of-care lactate/POCUS, EMR tools and shock teams. The authors explicitly favor sensitivity over specificity for early recognition.

Some personal comments:

1. “Therapy doesn’t define stage” isn’t completely clean. Table 2 (attached) uses escalating pressors or added MCS as evidence for D and bolus pressors as a feature of E. That makes sense because D is fundamentally about response to treatment. The real problem is that treatment varies between hospitals, operators and available resources. I’d call that confounding more than subjectivity.

2. The fix may be more subjective than the problem. Table 2 is full of “typically includes” and “may include,” with no minimum number of criteria and no inter-rater data. Try this one: warm patient on epinephrine, lactate 2.3, CI 2.4, normal mentation, good urine output. What stage? Two good intensivists may disagree.

3. This document is expert consensus, not high-level evidence. A narrative review plus a vote isn’t a systematic review. The decision to keep normotensive hypoperfusion in C is a consensus choice, and the paper itself discusses CSWG data that classified it differently. Stage A remains the least validated part of the framework.

4. Sensitivity over specificity widens the net, especially with Stage A, and could dilute what each stage means.

5. Many authors disclose relationships with device companies. Members with relevant significant conflicts did not vote, an important safeguard, but this remains worth knowing when reading a consensus document in an MCS-heavy field.

6. It’s a classification, not a treatment algorithm. Moving from C to D tells you the initial strategy is failing. It doesn’t tell you what to do next, and Table 4 essentially lists the available options.

Useful common language and a reasonable consensus, in my view, but not a validated decision tool.

How do you stage cardiogenic shock where you work? And do you restage after ECMO goes in?

#CardiogenicShock #SCAI #FOAMcc #Foamed
1 replies 2 reposts 14 likes 2.4K views View on X
IMCrit Verified account @IM_Crit_
#ICU / #ED Evidence #007: What if we bring ECMO to the patient instead of bringing the patient to ECMO?

We know ECPR is a race against time, but in most systems we still transport a patient receiving CPR to the hospital before ECMO can even start. The OnScene study, published today in NEJM, asked whether bringing the ECMO team to the patient could change that.

The investigators studied 231 patients ≤ 50 years old with refractory out-of-hospital cardiac arrest in a nationwide Dutch helicopter EMS system. Patients attended by HEMS with prehospital ECPR capability were compared with those receiving conventional care.

The results are hard to ignore:

Survival to hospital discharge: 40% vs 20%
Favorable neurologic outcome at 6 months: 36% vs 13%

And here is probably the number that matters most: median time to ECMO blood flow was 45 minutes with prehospital ECPR (83 patients) vs 77 minutes among the 19 patients who eventually received in-hospital ECPR in the conventional-care group.

That is 32 minutes. In refractory cardiac arrest, 32 minutes is a very long time. The comparator group is tiny and the comparison is nonrandomized, so I would read this as a very interesting signal, not proof that the location of cannulation made the difference.

Before we start putting ECMO machines in every helicopter, though, this was not a randomized trial. The patients were highly selected: only 231 ultimately entered the analysis from 3,362 study-related HEMS dispatches for suspected cardiac arrest. Shockable rhythms were more common in the intervention group (89% vs 75%), neurologic outcome was assessed unblinded, residual confounding is very possible, and cannulation failed in 15% of prehospital attempts (vs 17% of hospital attempts).

So I don’t think OnScene proves that prehospital ECPR is superior to in-hospital ECPR. I think it raises a more interesting question: are we focusing too much on where ECPR happens and not enough on how quickly we establish effective extracorporeal blood flow?

The accompanying editorial by Dr. Demetris Yannopoulos (@DYannopoulos), one of the pioneers in the field, makes another important point. Instead of sequential care (EMS resuscitates, transports, then the hospital prepares for ECPR), perhaps we should think in parallel: identify potential candidates early, mobilize the ECPR team while conventional resuscitation continues, and have the receiving hospital preparing at the same time.

Sometimes the fastest route to ECMO will be bringing the patient to the team. Sometimes it may be bringing the team to the patient. Geography, resources and expertise will matter.

The goal isn’t earlier cannulation. It’s earlier successful reperfusion. That, to me, is the real message of OnScene.

If your system could get ECMO flowing within 45 minutes, would you build it? And who would you pick?

And one last thought: if AI is the hottest thing in tech and finance these days, ECMO is surely the hottest thing in Critical Care.

#ECPR #ECMO #CardiacArrest #FOAMcc #Foamed